Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.

Jayesh Desai,Mark Voskoboynik,Ben Markman,Jeannie Hou,Dewan Zeng,Tarek M. Meniawy

Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.

2018

Jayesh Desai
Mark Voskoboynik
Ben Markman
Jeannie Hou
Dewan Zeng
Tarek M. Meniawy

TPS3113Background: Programmed cell death-1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1), play critical roles in the immune modulation of tumor progression. Tislelizumab is a humanized I...

Keywords:

Anti-PD-L1 Monoclonal Antibody
Anti-PD-1 Monoclonal Antibody
Pathology
Tolerability
Pharmacology
Medicine
Pharmacokinetics
antitumor activity
safety tolerability
in patient
Cancer research
Tumor progression
Cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations